SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca ... be safe and effective administered in twice-yearly ...

After 56 weeks, the average plasma concentrations of intramuscular lenacapavir exceeded those associated with efficacy in phase 3 studies of a subcutaneous injection (an injection under the skin ...

Persons who report intravascular, intramuscular, or subcutaneous injection of drugs for nonmedical reasons in the preceding 5 years. Persons with hemophilia or related clotting disorders who have ...

The subcutaneous degarelix injection was associated with a higher rate of injection-site reactions compared with the intramuscular leuprolide injection. The local reactions with degarelix occurred ...